indantadol

NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain; structure in first source

Also Known As:

CHF 3381; N-(2-indanyl)glycinamide; N-(2-indanyl)glycinamide hydrochloride

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Glycine: 5151
    - indantadol: 3
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Indenes: 4
        Indans: 7
        indantadol: 3
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Indenes: 4
    - Indans: 7
      - indantadol: 3

Experts

1.	Coluzzi, Flaminia: 1 article (09/2007)
2.	Mattia, Consalvo: 1 article (09/2007)
3.	Bonfante, V: 1 article (09/2001)
4.	Dall'Olio, R: 1 article (09/2001)
5.	Gandolfi, O: 1 article (09/2001)
6.	Pietra, C: 1 article (09/2001)
7.	Poli, A: 1 article (09/2001)
8.	Villetti, G: 1 article (09/2001)
9.	Voltattorni, M: 1 article (09/2001)

Related Diseases

1.	Neuralgia (Stump Neuralgia) 09/01/2007 - "Given the results available to date, indantadol may have a role in the treatment of neuropathic pain if the favorable pharmacokinetic profile and efficacy of the drug are maintained in more extensive clinical trials." 09/01/2007 - "Indantadol is currently in phase II clinical trials in patients with diabetic peripheral neuropathic pain. " 01/01/2004 - "At the 1st Annual BioPartnering North America (BPN-2003) it was stated that CHF 3381 is being evaluated for the treatment of neuropathic pain. " 09/01/2007 - "Indantadol is an oral and nonselective monoamine oxidase inhibitor and NMDA antagonist that is being developed by Vernalis plc, under license from Chiesi Farmaceutici SpA, for the potential treatment of neuropathic pain. " 09/01/2007 - "Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain."
2.	Seizures (Absence Seizure) 09/01/2001 - "Following intraperitoneal or oral administrations, CHF 3381 ([n-(2-indanyl)-glycinamide hydrochloride]) protected rats against maximal electroshock (MES) test seizures. " 09/01/2007 - "In preclinical studies, indantadol exhibited neuroprotective effects after kainite-induced seizures, and displayed anticonvulsant and antihyperalgesic activity. "
3.	Chronic Pain 01/01/2004 - "Chiesi also has rights to the European patent application for use of glycinamide derivatives (including CHF 3381) in the treatment of chronic pain."
4.	Pain (Aches) 09/01/2007 - "In a human heat-capsaicin-induced pain model, indantadol at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. "
5.	Hyperalgesia 09/01/2007 - "In a human heat-capsaicin-induced pain model, indantadol at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. "

Related Drugs and Biologics

1.	Neuroprotective Agents
2.	Anticonvulsants (Antiepileptic Drugs)
3.	N-Methylaspartate (NMDA)
4.	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
5.	glycine amide
6.	Excitatory Amino Acid Antagonists
7.	Dizocilpine Maleate (Dizocilpine)
8.	Spermidine
9.	Ligands
10.	Capsaicin (Zostrix)

Related Therapies and Procedures

1.	Oral Administration